Literature DB >> 33390136

Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers.

Raju Biswas1, Dipanjana Ghosh1, Bhramar Dutta1, Urmi Halder1, Prittam Goswami2, Rajib Bandopadhyay1.   

Abstract

Cancer therapy describes the treatment of cancer, often with surgery, chemotherapy, and radiotherapy. Additionally, RNA interference (RNAi) is likely to be considered a new emerging, alternative therapeutic approach for silencing/targeting cancer-related genes. RNAi can exert antiproliferative and proapoptotic effects by targeting functional carcinogenic molecules or knocking down gene products of cancer-related genes. However, in contrast to conventional cancer therapies, RNAi based therapy seems to have fewer side effects. Transcription signal sequence and conserved sequence analysis-showed that microorganisms could be a potent source of non-coding RNAs. This review concluded that mapping of RNAi mechanism and RNAi based drug delivery approaches is expected to lead a better prospective of cancer therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cancer therapy; RNA interference; RNAi based therapy; carcinogenic; drugs delivery; microorganisms

Year:  2021        PMID: 33390136     DOI: 10.2174/1566523220999201230204814

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  3 in total

1.  Identification of Nine mRNA Signatures for Sepsis Using Random Forest.

Authors:  Jing Zhou; Siqing Dong; Ping Wang; Xi Su; Liang Cheng
Journal:  Comput Math Methods Med       Date:  2022-03-19       Impact factor: 2.238

2.  Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel.

Authors:  Ling Li; Fangfang Chen; Jingcheng Liu; Weifeng Zhu; Liang Lin; Li Chen; Yi Shi; An Lin; Gang Chen
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

3.  Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.

Authors:  Mingrui Wu; Lan Liang; Xiaotian Dai
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.